Rhabdomyolysis With Abiraterone Exposure: A Brief Review of the Food and Drug Administration Adverse Event Reporting System (FAERS)

Abstract

Get full access to this article

View all access options for this article.

References

de Bono

Logothetis

Molina

et al . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. doi:10.1056/NEJMoa1014618

Fizazi

Tran

Fein

et al . LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360. doi:10.1056/NEJMoa1704174

Neyra

Rocha

Bhargava

et al . Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC Nephrol. 2015;16:118. doi:10.1177/1078155217701294

Moore

Abiraterone-induced rhabdomyolysis: a case report. J Oncol Pharm Pract. 2017;23:148-151. doi:10.1177/1078155215620921

Dineen

Hansen

Guancial

et al . Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: a case report and review of the literature. J Oncol Pharm Pract. 2018;24:314-318. doi:10.1177/1078155217701294

Zimmerman

Shen

MC.

Rhabdomyolysis. Chest. 2013;144:1058-1065. doi:10.1378/chest.12-2016

US Food and Drug Administration. Questions and answers on FDA’s Adverse Event Reporting System (FAERS). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed April 30, 2018.